查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1850500

药物筛检市场按技术、药物类型、样品类型和最终用户划分－2025-2032年全球预测

Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物筛检市场规模将达到 299.8 亿美元，复合年增长率为 14.86%。

关键市场统计数据
基准年 2024 98.9亿美元
预计年份：2025年 113.6亿美元
预测年份 2032 299.8亿美元
复合年增长率 (%) 14.86%

一个简洁的策略问题框架，驱动着不断变化的药物筛检环境、相关人员、实验室和采购决策。

由于技术进步、监管环境的变化以及应用场景从临床诊断到职场合规性的多元化，药物筛检领域正在迅速发展。本概要介绍了正在改变筛检专案设计、实施和管理方式的核心驱动力，在深入分析之前为读者提供简明扼要的指导。它综合了关键发展动态——包括分析平台、检体处理方法、终端用户需求以及跨境贸易的影响——从而明确了近期战略要务。

本导言首先清楚说明了研究范围和目标，并透过识别关键相关人员及其面临的决策（包括实验室、製造商、医疗保健提供者、雇主和监管机构）来建立后续章节的框架。它着重强调了技术选择、样本工作流程和法规遵从性之间的相互关联，同时指出了推动技术创新应用的商业性压力。最后，它概述了用于得出调查方法，使读者能够理解后续结论和建议的基础。

分析正在重新定义全球药物筛检进行和管理方式的重大技术、监管和营运变革

近年来，药物筛检生态系统发生了多项变革性变化，重塑了其功能和价值提案。首先，分析仪器的进步提高了检测灵敏度和特异性，从而能够更快、更准确地识别复杂基质中的物质。其次，数位化工作流程和实验室资讯学的整合简化了端到端流程，缩短了周转时间，同时提高了资料的完整性和可追溯性。第三，向分散式即时侦测模式的转变扩大了侦测范围，但也同时在非传统环境中提出了新的验证和品质保证要求。

同时，监管环境日趋动态，监管机构不断完善检测性能、监管炼和结果报告的标准，以适应技术发展和公共卫生需求。供应链韧性已成为一项策略重点，迫使製造商和服务供应商实现采购和库存策略的多元化。此外，相关人员对透明度和临床有效性的期望不断提高，这也对分析结果及其背景解释提出了更高的要求。综上所述，这些变化要求制定适应性策略，在采用技术创新的同时，兼顾严格的检验和营运扩充性。

评估2025年美国关税调整如何重塑科学研究设施的供应链韧性、筹资策略和营运连续性

2025年关税及贸易政策调整的实施，为依赖跨境采购试剂、仪器零件和耗材的製造商、经销商和实验室带来了明显的摩擦。对于供应链跨越多个司法管辖区的机构而言，进口关税的增加及其相关的行政成本延长了采购週期，并迫使其重新审视供应商合约和库存缓衝。在营运层面，实验室正在透过审查供应商组合、加快替代供应商的资格认证，以及在某些情况下将部分生产活动迁回国内来应对这些挑战，以降低关税波动带来的风险。

除了采购之外，关税也在影响价格谈判和资本支出决策。买家正在考虑设备的整体拥有成本，这可能会增加进口成本；服务提供者则在重新调整定价模式，以在不牺牲品质的前提下保护净利率。前置作业时间的延长促使实验室优化预测性订购，并投资于维护和备件策略，以确保检测服务的连续性。摘要，政策的转变已将供应链管理从一项战术性职能提升为一项策略能力，直接影响营运韧性和成本结构。

详细的細項分析将技术、分析物、样品类型和最终用户需求与可操作的检验和商业化路径连结起来

对细分市场的深入分析揭示了不同技术平台、分析物类别、检体类型和最终用户类别之间的差异化驱动因素，这些因素决定了技术的采用路径和价值提案。在化学冷光层面，层析法平台仍然是确证检测的核心，其中气相层析法在挥发性分析物方面表现出色，而液相层析法具有从极性化合物到非极性化合物的广泛适用性。免疫测量具有成本效益高的可扩展性和高通量筛选能力，化学发光方法提高了灵敏度，而酵素连结免疫层析法试验（ELISA）和萤光法则提供了高通量筛检能力。质谱技术，特别是用于挥发性和热稳定性化合物的气相层析-质谱联用技术以及用于多分析物组合的液相层析-串联式质谱质谱联用技术，正逐渐成为最终鑑定的黄金标准。这些平台之间的转换通常需要在通量、灵敏度和操作复杂性之间进行权衡。

在考虑药物类型细分时，传统检测方法仍侧重于兴奋剂、镇静剂和类大麻素；安非他命和古柯碱需要完善的确认流程，而鸦片类药物（细分为可待因、海洛因和氢可酮）则需要能够区分代谢物并考虑交叉反应的检测方法。离胺酸和四氢大麻酚是法医学和临床环境中的重要目标。检体类型细分决定了检测流程的设计。血液和尿液仍然是临床准确性和历史可比性的基础；毛髮具有较长的检测窗口，非常适合法医学的时间线；口腔液和唾液便于进行非侵入性的现场筛检，这会影响证据炼和确认性检测。临床实验室优先考虑诊断有效性和电子健康记录集成，戒毒中心强调长期监测和患者参与，刑事鑑定实验室强调证据的严谨性和法庭辩护能力，家庭检测需要用户友好的界面和清晰的说明，而职场检测则需要在速度和法规遵从性之间取得平衡。了解这些部分如何相互作用，对于协调产品开发、检验通讯协定和商业策略至关重要。

区域比较分析概述了管理体制、采购模式和基础设施的差异如何导致世界主要地区采取不同的采用策略。

区域动态持续影响技术应用、监管重点和商业策略，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，完善的实验室基础设施和一体化的医疗保健系统支援高效能确认平台的快速普及，而监管机构则强调临床有效性和资料互通性。该地区私营部门在职场和消费者检测解决方案方面也高度参与，推动了竞争性商业化模式和产品的多样化。

欧洲、中东和非洲各地法律规范的差异，要求製造商和服务供应商优先开发能够满足不同合规要求的适应性产品。多个市场正在增加对法医学能力的投资，公共卫生措施也影响筛检计画中优先考虑的检测类型。亚太地区既有成熟市场也有新兴市场，加速了扩充性、高性价比解决方案的需求。随着相关人员在寻求统一的最佳实践的同时，努力平衡本地监管限制与国际分析标准，跨区域合作和知识交流变得日益重要。

策略竞争概览，重点在于将塑造市场定位的创新丛集、伙伴关係模式和服务导向业务转型。

药物筛检生态系统的竞争格局呈现出强劲的态势，其特点是仪器和检测化学领域的密集创新，以及将检测、资讯学和合规支持整合在一起的服务型经济的蓬勃发展。领先企业正投资于用于高通量筛检和确证分析的模组化平台，而其他企业则透过整合软体解决方案来增强结果解读和监管链管理，从而实现差异化竞争。仪器製造商和试剂供应商之间的策略联盟日益普遍，以确保相容性并加快新检测方法的验证速度。

在质谱、照护现场诊断和实验室自动化等高需求领域，併购、策略联盟和定向收购不断重塑竞争格局。此外，监管科学和临床检验测试方面的投资仍然是准入壁垒，尤其是在需要法医学辩护和临床认证的领域。最后，以订阅方式提供託管测试和分析能力的面向服务的经营模式正在扩大市场覆盖范围，使小型实验室和非传统终端用户无需大量资本支出即可获得先进的测试方法。

清晰、优先排序的营运和策略建议，领导者可以实施这些建议以加速推广应用、降低风险并增强长期竞争力。

产业领导者应优先采取一系列切实可行的措施，以确保在快速变化的环境中保持竞争优势和营运韧性。首先，企业必须使其产品开发蓝图与检验的临床和法医学要求保持一致，并投资进行严谨的性能研究，以预测监管预期和最终用户的工作流程。其次，供应链多元化和策略性库存管理，以及针对关税波动、零件短缺和物流中断等情况的情境规划，应成为风险缓解的核心。

第三，各机构应加快采用数位化实验室资讯系统和分析技术，以提高吞吐量、确保资料完整性并实现关键设备的预测性维护。第四，各机构应推行模组化经营模式，将硬体、耗材和服务结合，以创造持续的收入来源，并降低分散用户的采用门槛。第五，相关人员必须投资于员工培训和认证项目，以随着技术的不断发展保持其专业水平。最后，积极与政策制定者、认证机构和专业协会合作，将有助于制定切实可行的法律规范和标准，从而降低创新者和采购者的不确定性。

对混合方法研究途径、检验步骤以及支持报告循证结论的局限性进行透明描述

本报告的研究结合了与领域专家和最终用户进行的初步研究和定性研究、结构化的二手资讯综合以及严格的交叉检验，以确保得出可靠且可操作的结论。初步研究包括对实验室主任、采购负责人、监管专家和技术供应商的访谈，以了解实际的限制因素、采购标准和检验经验。二手研究包括同行评审文献、监管指南、技术白皮书和供应商提交的检验摘要，所有这些都经过系统评估，以确保其相关性和方法论的严谨性。

我们运用资料三角测量技术来调和公开文献与医疗服务提供者证词之间的差异，并进行了敏感性检验，以确保我们的定性结论并非由孤立的个案所驱动。在适用情况下，我们开发了案例研究，阐述部署路径、供应链协调和检验时间表，以支援我们的建议。最后，我们承认本调查方法的限制：受访者样本可能偏向早期采用者，且技术的快速创新可能会缩短战术性建议的有效期限。为了降低这些风险，本研究强调策略原则和流程导向的建议，旨在使其在技术预期发展轨迹之外仍保持相关性。

综合各项研究结果，将技术、营运和监管主题连结起来，形成一个可供组织决策和投资使用的实用蓝图。

最后，现代药物筛检格局的特点是技术融合加速、监管预期不断变化以及供应链敏感性日益增强。这些因素既为企业差异化创造了机会，也为业务永续营运带来了挑战。卓越的企业将是那些投资于经过检验、可互通的技术、构建稳健的采购和维护能力，并将分析技术的进步与临床、法医学、职场和消费者等领域的明确用户提案主张相结合的企业。

展望未来，能否将高灵敏度的确诊工具整合到高效的筛检流程中，并辅以强大的资讯学和品质体系，将决定哪些医疗机构能够在性能和规模上都处于领先地位。相关人员应将本文的研究结果视为投资、营运和政策参与的策略蓝图，以期在检测可靠性、週转时间和成本效益方面取得可衡量的改善。本文提出的建议旨在指导实际行动，同时适应新的技术创新和监管发展。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在职场整合以人工智慧驱动的质谱平台进行超灵敏检测
  • 扩大家用套件的种类，方便消费者快速采集唾液及口腔液样本。
  • 引入基于区块链的监管链解决方案，以确保药物检测样本的完整性
  • 法医学实验室越来越多地采用非侵入性毛髮和指甲分析进行更广泛的检测
  • 用于同时检测尿液中新型合成鸦片类药物和类大麻素的多重免疫检测方法取得了进展
  • 不同司法管辖区的监管协调推动了照护现场设备核准流程的通讯协定。
  • 将快速口腔液检测结果与机器学习演算法结合，用于预测成瘾治疗中的復发风险

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的药物筛检市场

  • 层析法
    • 气相层析法
    • 液相层析法
  • 免疫检测
    • 化学冷光免疫检测
    • 酶联萤光测定法
    • 酵素结合免疫吸附试验
  • 质谱分析
    • 气相层析法质谱联用
    • 液相层析-串联式质谱质谱法

9. 按药物类型分類的药物筛检市场

  • 安非他命
  • 古柯碱
  • 阿片类药物
    • 可待因
    • 海洛因
    • 氢可酮
  • 离胺酸
  • 四氢大麻酚

10. 按样本类型分類的药物筛检市场

  • 血
  • 头髮
  • 口腔液
  • 唾液
  • 尿

第十一章 按最终用户分類的药物筛检市场

  • 临床实验室
  • 药物治疗中心
  • 法医学研究所
  • 家庭测试
  • 职场测试

12. 各地区药物筛检市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 药物筛检市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国药物筛检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Quest Diagnostics Incorporated
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Abbott Laboratories
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • Becton, Dickinson and Company
    • Sysmex Corporation
Product Code: MRR-DD6333AE5B92

The Drug Screening Market is projected to grow by USD 29.98 billion at a CAGR of 14.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.89 billion
Estimated Year [2025] USD 11.36 billion
Forecast Year [2032] USD 29.98 billion
CAGR (%) 14.86%

Concise framing of the evolving drug screening environment, stakeholders, and the strategic questions driving laboratory and procurement decisions

The drug screening landscape is undergoing rapid evolution driven by technological progress, shifting regulatory expectations, and growing diversity in use cases ranging from clinical diagnostics to workplace compliance. This executive brief introduces the core forces reshaping how screening programs are designed, executed, and governed, offering readers a concise orientation before deeper analysis. It synthesizes key developments across analytical platforms, specimen handling practices, end-user requirements, and cross-border trade influences that together define near-term strategic imperatives.

Beginning with a clear statement of scope and objectives, this introduction frames the subsequent sections by identifying the principal stakeholders-laboratories, manufacturers, healthcare providers, employers, and regulators-and the decisions they face. The narrative emphasizes the interconnectedness of technology selection, sample workflow, and regulatory adherence while highlighting the commercial pressures that drive innovation adoption. Finally, it outlines the methodological approach and the types of evidence used to derive insights, ensuring readers understand the basis for the conclusions and recommendations that follow.

Analysis of the major technological, regulatory, and operational shifts that are redefining how drug screening is performed and governed globally

Recent years have produced several transformative shifts that are redefining the drug screening ecosystem, altering both capability and value propositions. First, advances in analytical instrumentation have accelerated detection sensitivity and specificity, enabling earlier and more accurate identification of substances across complex matrices. Second, the integration of digital workflows and laboratory informatics is streamlining end-to-end processes, reducing turnaround times while improving data integrity and traceability. Third, the movement toward decentralized and point-of-care testing formats has expanded access but has also created new validation and quality-assurance requirements for non-traditional settings.

Concurrently, regulatory landscapes are becoming more dynamic, with authorities refining standards for assay performance, chain-of-custody, and result reporting to match technological possibilities and public health needs. Supply chain resilience has emerged as a strategic priority, prompting manufacturers and service providers to diversify sourcing and inventory strategies. Finally, stakeholder expectations around transparency and clinical relevance are raising the bar for both analytical outcomes and the contextual interpretation of results. Taken together, these shifts necessitate adaptive strategies that balance innovation adoption with rigorous validation and operational scalability.

Assessment of how 2025 tariff shifts in the United States are reshaping supply chain resilience, procurement strategies, and operational continuity in laboratories

The introduction of tariffs and trade policy adjustments in 2025 has created measurable friction for manufacturers, distributors, and laboratories that depend on cross-border sourcing of reagents, instrumentation components, and consumables. For organizations whose supply chains span multiple jurisdictions, increased import duties and associated administrative costs have lengthened procurement cycles and necessitated revisions to supplier contracts and inventory buffers. At the operational level, laboratories are responding by reassessing vendor portfolios, accelerating qualification of alternate suppliers, and in some cases repatriating certain manufacturing activities to reduce exposure to tariff volatility.

Beyond procurement, tariffs have influenced pricing negotiations and capital-expenditure decisions. Buyers are weighing the total cost of ownership for instruments that may now carry incremental import costs, and service providers are recalibrating pricing models to preserve margins without compromising quality. Indirect consequences are also evident: extended lead times are prompting laboratories to optimize predictive ordering and to invest in maintenance and spares strategies that maintain continuity of testing services. In summary, policy shifts have elevated supply chain management from a tactical function to a strategic competency that directly impacts operational resilience and cost structures.

In-depth segmentation analysis linking technologies, analyte targets, sample types, and end-user requirements to practical validation and commercialization pathways

A granular view of segmentation reveals differentiated drivers across technology platforms, analyte classes, specimen types, and end-user categories that determine adoption pathways and value propositions. On the technology axis, chromatography platforms remain central for confirmatory testing, with gas chromatography providing strength in volatile analytes and liquid chromatography offering broad applicability across polar and nonpolar compounds; immunoassays deliver high-throughput screening capability with chemiluminescent approaches offering sensitivity gains while ELISA and fluorescent formats provide cost-effective scalability; mass spectrometry techniques, notably gas chromatography mass spectrometry for volatile and thermal-stable compounds and liquid chromatography-tandem mass spectrometry for multi-analyte panels, are increasingly the gold standard for definitive identification. Transitioning between these platforms often involves trade-offs between throughput, sensitivity, and operational complexity.

When examining drug type segmentation, traditional panels continue to emphasize stimulants, depressants, and cannabinoids, with amphetamines and cocaine requiring robust confirmatory workflows, while opiates-subdivided into codeine, heroin, and morphine-demand assays that distinguish metabolites and account for cross-reactivity. Phencyclidine and tetrahydrocannabinol remain important targets for both forensic and clinical use cases. Sample type segmentation drives procedural design: blood and urine remain foundational for clinical accuracy and historical comparability, hair provides extended detection windows suitable for forensic timelines, and oral fluid and saliva facilitate noninvasive, on-site screening with implications for chain-of-custody and confirmatory testing. End-user segmentation highlights distinct requirements: clinical laboratories prioritize diagnostic validity and integration with electronic health records, drug treatment centers focus on longitudinal monitoring and patient engagement, forensic laboratories emphasize evidentiary rigor and courtroom defensibility, home testing demands user-friendly interfaces and clear instructions, and workplace testing balances speed with legal compliance. Understanding how these segments interact is essential for tailoring product development, validation protocols, and commercial strategies.

Comparative regional intelligence outlining how regulatory regimes, procurement models, and infrastructure differences drive distinct adoption strategies across major global regions

Regional dynamics continue to shape technology uptake, regulatory priorities, and commercial strategies, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory infrastructure and integrated healthcare systems support rapid adoption of high-performance confirmation platforms, while regulatory bodies emphasize clinical validity and data interoperability. This region also demonstrates a high degree of private-sector involvement in workplace and consumer testing solutions, which drives competitive commercialization models and service diversification.

Across Europe, Middle East & Africa, regulatory frameworks are heterogeneous, prompting manufacturers and service providers to prioritize adaptable products that can meet divergent compliance requirements. Investment in forensic capabilities is growing in several markets, and public-health initiatives are influencing the types of assays prioritized for screening programs. In the Asia-Pacific region, a mix of mature and emerging markets is accelerating demand for scalable, cost-efficient solutions; local manufacturing capabilities and government-led procurement strategies shape pricing and distribution dynamics. Cross-region collaboration and knowledge exchange are increasingly important as stakeholders seek harmonized best practices that balance local regulatory constraints with international analytical standards.

Strategic competitive overview highlighting innovation clusters, partnership models, and service-oriented business transformations that influence market positioning

Competitive dynamics in the drug screening ecosystem are characterized by concentrated innovation in instrumentation and assay chemistries, alongside a proliferating services economy that bundles testing, informatics, and compliance support. Leading organizations are investing in modular platforms that accommodate both high-throughput screening and confirmatory analyses, while others are differentiating through integrated software solutions that enhance result interpretation and chain-of-custody management. Strategic collaborations between instrument manufacturers and reagent suppliers are becoming more common to ensure compatibility and to accelerate time-to-validation for new assays.

Mergers, strategic partnerships, and targeted acquisitions continue to reshape the competitive landscape as companies seek capabilities in high-demand areas such as mass spectrometry, point-of-care diagnostics, and laboratory automation. Additionally, investments in regulatory science and clinical validation studies serve as durable barriers to entry, particularly in sectors where forensic defensibility or clinical accreditation is required. Finally, service-oriented business models that offer managed testing and subscription-based access to analytic capacity are increasing market reach, enabling smaller laboratories and non-traditional end users to access advanced testing modalities without large capital expenditures.

Clear and prioritized operational and strategic recommendations that leaders can implement to accelerate adoption, reduce risk, and strengthen long-term competitiveness

Industry leaders should prioritize a set of actionable measures to secure competitive advantage and operational resilience in a rapidly evolving environment. First, firms must align product development roadmaps with validated clinical and forensic requirements, investing in rigorous performance studies that anticipate regulatory expectations and end-user workflows. Second, supply chain diversification and strategic inventory management should be elevated to core risk-mitigation practices, with scenario planning for tariff fluctuations, component shortages, and logistics disruptions.

Third, adoption of digital laboratory information systems and analytics should be accelerated to improve throughput, ensure data integrity, and enable predictive maintenance of critical instrumentation. Fourth, organizations should pursue modular business models that combine hardware, consumables, and services to create recurring revenue streams and to lower adoption barriers for decentralized users. Fifth, stakeholders must invest in workforce training and certification programs that maintain proficiency as technologies evolve. Finally, proactive engagement with policymakers, accreditation bodies, and professional associations will help shape practical regulatory frameworks and standards, reducing uncertainty for innovators and purchasers alike.

Transparent explanation of the mixed-methods research approach, validation steps, and limitations that underpin the report's evidence-based conclusions

The research behind this report combines primary qualitative engagements with subject-matter experts and end users, structured secondary-source synthesis, and rigorous cross-validation to ensure robust and actionable findings. Primary inputs included interviews with laboratory directors, procurement leads, regulatory specialists, and technology vendors to capture real-world constraints, procurement criteria, and validation experiences. Secondary research encompassed peer-reviewed literature, regulatory guidances, technical whitepapers, and provider-submitted validation summaries, all systematically evaluated for relevance and methodological rigor.

Data triangulation techniques were used to reconcile discrepancies between public literature and practitioner accounts, and sensitivity checks were applied to qualitative conclusions to ensure they were not driven by isolated anecdotes. Where applicable, case studies illustrating deployment pathways, supply chain adjustments, and validation timelines were developed to anchor recommendations. Finally, the methodology acknowledges limitations: respondent samples may over-represent early adopters, and rapid technological change can shorten the shelf life of tactical recommendations. To mitigate these risks, the study emphasizes strategic principles and process-oriented recommendations designed to remain relevant across expected technology trajectories.

Concluding synthesis that ties together technological, operational, and regulatory themes into a pragmatic blueprint for organizational decision-making and investment

In closing, the contemporary drug screening landscape is defined by accelerated technological convergence, shifting regulatory expectations, and heightened supply chain sensitivity. These forces create both opportunities for differentiation and challenges to operational continuity. Organizations that excel will be those that invest in validated, interoperable technologies; that build resilient procurement and maintenance capabilities; and that translate analytical advances into clear user-value propositions across clinical, forensic, workplace, and consumer contexts.

Looking forward, the capacity to integrate high-sensitivity confirmatory tools with efficient screening workflows, supported by robust informatics and quality systems, will determine which providers lead in both performance and scale. Stakeholders should interpret the findings herein as a strategic blueprint for aligning investment, operations, and policy engagement to achieve measurable improvements in test reliability, turnaround, and cost-efficiency. The recommendations provided are intended to guide pragmatic action while remaining adaptable to emerging innovations and regulatory developments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven mass spectrometry platforms for ultrasensitive drug screening in workplace testing
  • 5.2. Expansion of at-home saliva and oral fluid collection kits for rapid consumer drug screening
  • 5.3. Deployment of blockchain-based chain-of-custody solutions to ensure integrity of drug test samples
  • 5.4. Rising adoption of noninvasive hair and fingernail analysis for extended window drug screening in forensic labs
  • 5.5. Advancements in multiplex immunoassay panels for simultaneous detection of emerging synthetic opioids and cannabinoids in urine
  • 5.6. Regulatory harmonization across jurisdictions driving standardized protocols for point-of-care drug screening device approvals
  • 5.7. Integration of machine learning algorithms with oral fluid rapid test results for predictive relapse risk assessment in addiction treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Screening Market, by Technology

  • 8.1. Chromatography
    • 8.1.1. Gas Chromatography
    • 8.1.2. Liquid Chromatography
  • 8.2. Immunoassay
    • 8.2.1. Chemiluminescent Immunoassay
    • 8.2.2. Enzyme-Linked Fluorescent Assay
    • 8.2.3. Enzyme-Linked Immunosorbent Assay
  • 8.3. Mass Spectrometry
    • 8.3.1. Gas Chromatography Mass Spectrometry
    • 8.3.2. Liquid Chromatography-Tandem Mass Spectrometry

9. Drug Screening Market, by Drug Type

  • 9.1. Amphetamines
  • 9.2. Cocaine
  • 9.3. Opiates
    • 9.3.1. Codeine
    • 9.3.2. Heroin
    • 9.3.3. Morphine
  • 9.4. Phencyclidine
  • 9.5. Tetrahydrocannabinol

10. Drug Screening Market, by Sample Type

  • 10.1. Blood
  • 10.2. Hair
  • 10.3. Oral Fluid
  • 10.4. Saliva
  • 10.5. Urine

11. Drug Screening Market, by End User

  • 11.1. Clinical Laboratories
  • 11.2. Drug Treatment Centers
  • 11.3. Forensic Laboratories
  • 11.4. Home Testing
  • 11.5. Workplace Testing

12. Drug Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Quest Diagnostics Incorporated
    • 15.3.2. Laboratory Corporation of America Holdings
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Roche Holding AG
    • 15.3.5. Abbott Laboratories
    • 15.3.6. Danaher Corporation
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Becton, Dickinson and Company
    • 15.3.10. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS DRUG SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 342. ASEAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN DRUG SCREE